{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:26:50Z","timestamp":1785594410035,"version":"3.56.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.anl.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T08:07:16Z","timestamp":1773648436000},"page":"328-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Conversion surgery following trastuzumab and docetaxel combination therapy for unresectable HER2-positive parotid gland cancer"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4750-5332","authenticated-orcid":false,"given":"Satoshi","family":"Kano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-8201","authenticated-orcid":false,"given":"Taku","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-4118","authenticated-orcid":false,"given":"Seijiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-0646","authenticated-orcid":false,"given":"Akihiro","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2026.03.001_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693394","article-title":"HER2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis","volume":"11","author":"Egebjerg","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.anl.2026.03.001_bib0002","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/PAS.0000000000002307","article-title":"Expanding the molecular spectrum of carcinoma ex pleomorphic adenoma: an analysis of 84 cases with a novel HMGA2::LINC02389 fusion","volume":"48","author":"de Lima-Souza","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anl.2026.03.001_bib0003","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of american pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2026.03.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107280","article-title":"The impact of HER2-Low expression in salivary duct carcinoma: clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy","volume":"165","author":"Kano","year":"2025","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2026.03.001_bib0005","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jjco\/hyaf106","article-title":"Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer","volume":"55","author":"Kano","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.anl.2026.03.001_bib0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II Trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2026.03.001_bib0007","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1002\/hed.28196","article-title":"Conversion surgery after administration of a TRK inhibitor for unresectable parotid gland secretory carcinoma","volume":"47","author":"Nagano","year":"2025","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2026.03.001_bib0008","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hed.26563","article-title":"Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy","volume":"43","author":"Zakeri","year":"2021","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2026.03.001_bib0009","doi-asserted-by":"crossref","first-page":"261","DOI":"10.14338\/IJPT-20-00044.1","article-title":"Proton therapy for major salivary gland cancer: clinical outcomes","volume":"8","author":"Hanania","year":"2021","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.anl.2026.03.001_bib0010","doi-asserted-by":"crossref","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.anl.2026.03.001_bib0011","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.18632\/oncotarget.22927","article-title":"Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas","volume":"9","author":"Shimura","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.anl.2026.03.001_bib0012","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1245\/s10434-015-5082-2","article-title":"Clinical outcomes and prognostic factors for salivary duct carcinoma: a multi-institutional analysis of 141 patients","volume":"23","author":"Otsuka","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.anl.2026.03.001_bib0013","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s40792-020-00984-w","article-title":"Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy","volume":"6","author":"Hayano","year":"2020","journal-title":"Surg Case Rep"},{"key":"10.1016\/j.anl.2026.03.001_bib0014","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.21037\/tcr-21-2886","article-title":"Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy","volume":"11","author":"Zhang","year":"2022","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.anl.2026.03.001_bib0015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2026.03.001_bib0016","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-24-0455","article-title":"Apalutamide and goserelin for androgen receptor-positive salivary gland carcinoma: a phase II nonrandomized clinical trial, YATAGARASU","volume":"30","author":"Honma","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2026.03.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221119538","article-title":"Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma","volume":"14","author":"Kawakita","year":"2022","journal-title":"Ther Adv Med Oncol"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814626000404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814626000404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:03:44Z","timestamp":1783634624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814626000404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0385814626000404"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2026.03.001","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conversion surgery following trastuzumab and docetaxel combination therapy for unresectable HER2-positive parotid gland cancer","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}